Literature DB >> 18682990

Metastatic bone pain: treatment options with an emphasis on bisphosphonates.

Roger von Moos1, Florian Strasser, Silke Gillessen, Kathrin Zaugg.   

Abstract

INTRODUCTION: One of the key targets for metastatic cancer cells is the skeleton. Once metastatic cells are established within the bone matrix, skeletal integrity becomes increasingly compromised. Bone lesions lead to various complications, including bone pain, fractures and spinal cord compression. MECHANISMS OF BONE PAIN: Bone pain is debilitating and affects quality of life of the patient. In addition, it increases the use of health care resources. Many patients with metastatic bone disease experience substantial bone pain despite state-of-the-art systemic analgesic treatment. Incident pain is the predominant pain syndrome. TREATMENT OPTIONS FOR BONE PAIN: Typically, this syndrome requires moderate baseline analgesia with increased on-demand doses. Other techniques for treating bone pain, including radiation therapy, neuraxial application of analgesics, nerve blocks and local stabilisation procedures, should be considered. In addition, therapy with bisphosphonates targeting bone-specific pain is an important strategy. This review discusses the various management options for bone pain arising from metastatic bone disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18682990     DOI: 10.1007/s00520-008-0487-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  94 in total

1.  Clinical application of the World Health Organization analgesic ladder.

Authors:  J A Dalton; R Youngblood
Journal:  J Intraven Nurs       Date:  2000 Mar-Apr

2.  Scoring the effect of radiotherapy for painful bone metastases.

Authors:  Sebastiano Mercadante
Journal:  Support Care Cancer       Date:  2006-03-30       Impact factor: 3.603

Review 3.  Malignant bone pain: pathophysiology and treatments.

Authors:  C Ripamonti; F Fulfaro
Journal:  Curr Rev Pain       Date:  2000

4.  Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.

Authors:  William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio
Journal:  J Natl Cancer Inst       Date:  2005-06-01       Impact factor: 13.506

Review 5.  Practice guidelines for transdermal opioids in malignant pain.

Authors:  Tracy L Skaer
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Bisphosphonates for breast cancer.

Authors:  N Pavlakis; Rl Schmidt; M Stockler
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

7.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

8.  Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Authors:  Lee S Rosen; David Gordon; N Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; Maciej Krzakowski; Marek Pawlicki; Paul De Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John Seaman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

Review 9.  Pain control by ionizing radiation of bone metastasis.

Authors:  Luc A M-L Vakaet; Tom Boterberg
Journal:  Int J Dev Biol       Date:  2004       Impact factor: 2.203

Review 10.  Antiepileptic drugs in the treatment of neuropathic pain.

Authors:  Elon Eisenberg; Yaron River; Ala Shifrin; Norberto Krivoy
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more
  12 in total

Review 1.  Bone cancer pain.

Authors:  Juan Miguel Jimenez-Andrade; William G Mantyh; Aaron P Bloom; Alice S Ferng; Christopher P Geffre; Patrick W Mantyh
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

2.  Nociceptive and pro-inflammatory effects of dimethylallyl pyrophosphate via TRPV4 activation.

Authors:  S Bang; S Yoo; T J Yang; H Cho; S W Hwang
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  Pathogenesis and clinical aspects of pain in patients with osteoporosis.

Authors:  Rocco Domenico Mediati; Renato Vellucci; Lucia Dodaro
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

4.  Farnesyl pyrophosphate is a novel pain-producing molecule via specific activation of TRPV3.

Authors:  Sangsu Bang; Sungjae Yoo; Tae-Jin Yang; Hawon Cho; Sun Wook Hwang
Journal:  J Biol Chem       Date:  2010-04-15       Impact factor: 5.157

Review 5.  Bone cancer pain: from mechanism to therapy.

Authors:  Patrick W Mantyh
Journal:  Curr Opin Support Palliat Care       Date:  2014-06       Impact factor: 2.302

Review 6.  Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.

Authors:  Donald L Patrick; Charles S Cleeland; Roger von Moos; Lesley Fallowfield; Rachel Wei; Katarina Öhrling; Yi Qian
Journal:  Support Care Cancer       Date:  2014-12-23       Impact factor: 3.603

7.  Balloon kyphoplasty in malignant spinal fractures: a systematic review and meta-analysis.

Authors:  Carmen Bouza; Teresa López-Cuadrado; Patricia Cediel; Zuleika Saz-Parkinson; José María Amate
Journal:  BMC Palliat Care       Date:  2009-09-09       Impact factor: 3.234

8.  Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.

Authors:  Roger von Moos; Jean-Jacques Body; Blair Egerdie; Alison Stopeck; Janet E Brown; Danail Damyanov; Lesley J Fallowfield; Gavin Marx; Charles S Cleeland; Donald L Patrick; Felipe G Palazzo; Yi Qian; Ada Braun; Karen Chung
Journal:  Support Care Cancer       Date:  2013-08-22       Impact factor: 3.603

9.  Mice with cancer-induced bone pain show a marked decline in day/night activity.

Authors:  Lisa A Majuta; Jean-Marc G Guedon; Stefanie A T Mitchell; Michael A Kuskowski; Patrick W Mantyh
Journal:  Pain Rep       Date:  2017-08-11

10.  Therapeutic and Preventive Effects of Osteoclastogenesis Inhibitory Factor on Osteolysis, Proliferation of Mammary Tumor Cell and Induction of Cancer Stem Cells in the Bone Microenvironment.

Authors:  Mitsuru Futakuchi; Takao Nitanda; Saeko Ando; Harutoshi Matsumoto; Eri Yoshimoto; Katsumi Fukamachi; Masumi Suzui
Journal:  Int J Mol Sci       Date:  2018-03-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.